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Abstract
Introduction: Fibroblast growth factor 21 (FGF 21) has been suggested as a predictor for the development of type 2 diabetes mellitus (T2DM). 
Material and methods: We aimed to determine FGF 21 levels in normoglycaemic (Group 1) and prediabetic (Group 2) first-degree relatives 
(FDR) of patients with T2DM in comparison with normoglycaemic subjects without a history of T2DM in their FDR (Group 3).
Results: There was a significant difference between Group 1, 2, and 3 with respect to plasma FGF 21 concentrations (143.3 ± 93.8, 221.9 ± 
± 171.7 and 121.2 ± 119.8 pg/mL, respectively, p = 0.01). FGF 21 levels were significantly increased in prediabetic FDR of patients with 
T2DM compared to normoglycaemic subjects without a history of T2DM in their FDR (p = 0.02). FGF 21 levels did not differ between 
normoglycaemic FDR of patients with T2DM and normoglycaemic subjects without a history of T2DM in their FDR (p > 0.05). In the whole 
group, FGF 21 correlated positively with age (r = 0.31, p = 0.003), BMI (r = 0.38, p < 0.001), systolic blood pressure (r = 0.38, p = 0.001), 
diastolic blood pressure (r = 0.26, p = 0.02), fasting blood glucose (r = 0.24, p = 0.02), HOMA-IR (r = 0.23, p = 0.03), AUC glucose (r = 0.35, 
p = 0.001), and AUC insulin (r = 0.32, p = 0.003) and negatively with HDL cholesterol (r = –0.24, p = 0.02) and Matsuda ISI (r = –0.33, 
p = 0.002). In the regression analysis, BMI was the most predictive factor for FGF 21 levels (b = 0.41, r2 = 0.17, p < 0.001).
Conclusions: We showed that FGF 21 concentrations are increased in prediabetic FDR of patients with T2DM and that there is a significant 
association between FGF 21 and obesity and insulin sensitivity. (Endokrynol Pol 2016; 67 (3): 260–264)
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Streszczenie
Wstęp: Sugerowano, że stężenie czynnika wzrostu fibroblastów 21 (FGF 21) jest czynnikiem predykcyjnym rozwoju cukrzycy typu 2 (T2DM). 
Materiał i metody: Celem badania było ustalenie stężenia FGF 21 u osób z normoglikemią (grupa 1) i ze stanem przedcukrzycowym (grupa 2) 
będących krewnymi pierwszego stopnia (FDR) chorych na T2DM w porównaniu z osobami z normoglikemią z ujemnym wywiadem 
rodzinnym w kierunku T2DM (grupa 3).
Wyniki: Stwierdzono istotne różnice między grupami 1, 2 i 3 pod względem stężenia FGF 21 w osoczu (odpowiednio 143,3 ± 93,8; 221,9 ± 
 ± 171,7 i 121,2 ± 119,8 pg/ml; p = 0,01). Stężenia FGF 21 były istotnie wyższe w grupie krewnych pierwszego stopnia chorych na T2DM 
ze stanem przedcukrzycowym niż u osób z normoglikemią bez dodatniego wywiadu rodzinnego w kierunku T2DM (p = 0,02). Stężenia 
FGF 21 nie różniły się istotnie między krewnymi pierwszego stopnia chorych na T2DM z normoglikemią a osobami z normoglikemią 
bez T2DM u krewnych pierwszego stopnia (p > 0,05). W całej badanej grupie stwierdzono dodatnią korelację między stężeniem FGF 
21 a wiekiem (r = 0,31; p = 0,003), BMI (r = 0,38; p < 0,001), skurczowym ciśnieniem tętniczym (r = 0,38; p = 0,001), rozkurczowym ci-
śnieniem tętniczym (r = 0,26; p = 0,02), glikemią na czczo (r = 0,24; p = 0,02), wskaźnikiem HOMA-IR (r = 0,23; p = 0,03), AUC glukozy 
(r = 0,35; p = 0,001), AUC insuliny (r = 0,32; p = 0,003) oraz ujemną korelację ze stężeniem cholesterolu frakcji HDL (r = –0,24; p = 0,02) 
i wskaźnikiem ISI według Matsudy (r = –0,33; p = 0,002). W analizie regresji najsilniejszym czynnikiem prognostycznym stężenia 
FGF 21 był wskaźnik BMI (b = 0,41; r2 = 0,17; p < 0,001).
Wnioski: Podsumowując, autorzy wykazali, że stężenia FGF 21 są zwiększone u krewnych pierwszego stopnia chorych na T2DM ze 
stanem przedcukrzycowym i że istnieje silny związek między stężeniem FGF 21 a otyłością i wrażliwością na insulinę. 
(Endokrynol Pol 2016; 67 (3): 260–264)
Słowa kluczowe: czynnik wzrostu fibroblastów 21; cukrzyca typu 2; wywiad; krewni pierwszego stopnia; wskaźnik masy ciała; otyłość
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Introduction
Subjects with a family history of type 2 diabetes mel-
litus (T2DM) have increased risk of T2DM, and this as-
sociation is independent of other risk factors, including 
obesity, insulin resistance, and lifestyle changes [1, 2]. 
It has been revealed that several metabolic defects may 
exist in normal glucose-tolerant first-degree relatives 
(FDR) of patients with T2DM [3]. Whole-body insulin 
resistance and decreased forearm glucose uptake have 
been shown in normoglycaemic FDR [4]. Decreased 
second-phase insulin release has also been shown in 
normal glucose-tolerant FDR [5].
Fibroblast growth factor 21 (FGF 21), a protein from 
the FGF family, is suggested to have an important role 
in carbohydrate and lipid metabolism and is mainly 
produced by liver (as well as by pancreas and white 
adipose tissue) [6]. In previous studies, increased levels 
of FGF 21 have been reported to be associated with 
some diseases in which insulin resistance plays a major 
role, such as obesity [7], T2DM [8], impaired glucose 
tolerance (IGT) [9], gestational diabetes mellitus [10], 
non-alcoholic steatohepatitis (NASH) [11], and meta-
bolic syndrome (MS) [7].
To the best of our knowledge, the blood levels of 
FGF 21 in the FDR of patients with T2DM is not known. 
The aim of the present study was to investigate FGF 21 
levels in the FDR of patients with T2DM according to 
their status for glucose tolerance in comparison with 
the subjects without history of T2DM in their FDR. 
Additionally, the relationship between FGF 21 and 
indices of insulin sensitivity, insulin resistance, and the 
existence of MS were examined. 
Material and methods
A total of 86 subjects attending our Diabetes and Obesity 
Clinics were enrolled in the study. The study protocol 
was approved by the Local Ethics Committee. Informed 
consent was obtained from all the subjects included in 
the study.
Eight-hour overnight fasting blood samples 
were collected from participants in the morning for 
biochemical evaluation. 75-gram oral glucose tolerance 
test (OGTT) [12] was performed in all subjects. A diet 
containing 300 g carbohydrate/day was advised at least 
three days before the test. Glucose and insulin levels 
were measured at 0, 30, 60, 90, and 120 minutes of OGTT. 
Blood samples for the measurement of FGF 21 were 
separated and stored at –80oC. The subjects enrolled in 
the study were divided into three groups according to 
the results of OGTT: Group 1 (n = 35): normoglycaemic 
FDR of patients with T2DM, Group 2 (n = 28): predia-
betic (IGT or impaired fasting glucose) FDR of patients 
with T2DM, Group 3 (n = 23): normoglycaemic subjects 
without history of T2DM in their FDR. MS was defined 
according to ATP III criteria [12].
Total cholesterol, triglycerides, HDL cholesterol, 
fasting blood glucose, AST, ALT, uric acid, and creatinine 
levels were measured by Olympus AU2700 plus model 
Beckman autoanalyser with enzymatic-spectrophoto-
metric methods. LDL cholesterol was calculated using 
the Friedewald formula. Insulin levels were measured 
by chemiluminescence method with an Abbott Architect 
i2000 autoanalyser. Plasma levels of FGF 21 were analysed 
using an Enzyme-linked immunosorbent assay (ELISA) 
kit (BioVendor Human FGF21 ELISA kit, Czech Republic). 
The sensitivity of the kit was 7 pg/mL and the intra-assay 
and inter-assay variations were < 5% and < 5%.
Areas under the glucose (AUCG) and insulin (AUCI) 
curves in OGTT were calculated by the trapezoidal rule. 
The homeostasis model assessment of insulin resistance 
(HOMA-IR) [13] and Matsuda index of insulin sensitiv-
ity (Matsuda ISI) [14] were calculated as previously 
published.
Statistical analyses
Statistical analyses were performed with SPSS for Win-
dows Version 21.0 software package. The numerical 
variables were expressed as mean ± standard deviation 
or median (minimum–maximum) values. The categori-
cal variables were presented by the number and were 
analysed using the chi-square test. Distribution of the 
data was examined with Shapiro-Wilk test, and homo-
geneity of variances were examined with Levene test. 
One-way analysis of variance or Welch ANOVA test was 
used to determine the differences between the groups 
if parametric test assumptions were provided. If there 
was a difference between three groups, Tukey HSD or 
Games Howell test was used for pairwise comparisons. 
If parametric test assumptions were not provided, 
Mann Whitney U test was used for comparison of two 
groups and Kruskal-Wallis test for three groups. Pearson 
or Spearman correlation coefficient was used to detect 
the associations between numeric variables in the whole 
group. Stepwise multiple linear regression analysis was 
performed to determine the factors affecting the level of 
FGF 21. A p value of < 0.05 was considered significant.
Results
The characteristics of the subjects in the study are 
shown in Table I. There were no significant differences 
in age, gender, BMI, waist-hip ratio, blood pressure, 
creatinine, ALT, uric acid, and lipids except triglyc-
erides between the three groups (p > 0.05). Fasting 
blood glucose, HOMA-IR, AUCG, AUCI, and Matsuda 
ISI were significantly different between the groups, 
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as seen in Table I. There was a statistically significant 
difference between Group 1, 2, and 3 with respect to 
plasma FGF 21 concentrations (143.3 ± 93.8, 221.9 ± 
± 171.7 and 121.2 ± 119.8 pg/mL, p = 0.01, respectively). 
FGF 21 levels were significantly increased in prediabetic 
FDR of patients with T2DM (Group 2) compared to 
normoglycaemic subjects without a history of T2DM 
in their FDR (Group 3) (p = 0.02). FGF 21 levels did not 
differ between normoglycaemic FDR of patients with 
T2DM (Group 1) and normoglycaemic subjects without 
a history of T2DM in their FDR (Group 3), (p > 0.05). 
The subjects with MS (n = 12) had increased FGF 21 
concentrations compared to the subjects without MS 
(n = 74) (275.0 ± 157.4 vs. 142.5 ± 124.0 pg/mL, p = 0.001).
Plasma FGF 21 levels were positively correlated with 
age (r = 0.31, p = 0.003), BMI (r = 0.38, p < 0.001), 
systolic blood pressure (r = 0.38, p = 0.001), diastolic 
blood pressure (r = 0.26, p = 0.02), fasting blood glucose 
(r = 0.24, p = 0.02), HOMA-IR (r = 0.23, p = 0.03), AUCG 
(r = 0.35, p = 0.001), and AUCI (r = 0.32, p = 0.003) 
and negatively with HDL cholesterol (r = –0.24, 
p = 0.02) and Matsuda ISI (r = –0.33, p = 0.002) in the 
whole group (Table II).
Multiple linear regression analysis (stepwise man-
ner) including age, BMI, systolic and diastolic blood 
pressure, fasting blood glucose, HDL cholesterol, 
HOMA-IR, AUCG, AUCI, and Matsuda ISI as inde-
Table II. The correlations of FGF 21 with metabolic para-
meters (n = 86)
Tabela II. Korelacje między FGF 21 a parametrami metabo-
licznymi (n = 86)
r p
Age 0.31 0.003
BMI 0.38  < 0.001
Systolic BP 0.38 0.001
Diastolic BP 0.26 0.02
FBG 0.24 0.02
HDL-cholesterol –0.24 0.02
HOMA-IR 0.23 0.03
AUCG 0.35 0.001
AUCI 0.32 0.003
Matsuda ISI –0.33 0.002
Table I. Characteristics of the subjects in the study
Tabela I. Charakterystyka uczestników badania
Group 1 [29] Group 2 (n = 28) Group 3 (n = 23) p for 3 groups
Age (years) 36.1 ± 9.6 40.3 ± 10.2 37.6 ± 8.8 > 0.05
Gender (F/M) 27/8 19/9 15/8 > 0.05
BMI [kg/m2] 27.6 ± 5.1 29.5 ± 4.8 26.6 ± 3.9 > 0.05
WHR [cm] 0.7 (0.6–1.0) 0.8 (0.7–1.0) 0.8 (0.7–0.9) > 0.05
Systolic BP [mm Hg] 110.0 (90.0–135.0) 120.0 (95.0–160.0) 110.0 (90.0–130.0) > 0.05
Diastolic BP [mm Hg] 70.0(50.0–95.0) 70.0 (60.0–100.0) 70.0 (60.0–80.0) > 0.05
FBG [mg/dL] 87.4 ± 8.0 99.5 ± 11.1a 88.1 ± 7.3 < 0.001
Creatinine [mg/dL] 0.6 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 > 0.05
ALT [mg/dL] 16.5 (3.0–66.0) 18.0 (8.0–56.0) 14.0 (9.0–75.0) > 0.05
Uric acid [mg/dL] 4.4 ± 1.3 5.0 ± 1.1 4.3 ± 1.0 > 0.05
Total cholesterol [mg/dL] 177.0 (117.0–298.0) 212.0 (134.0–359.0) 184.0 (151.0–291.0) > 0.05
LDL-cholesterol [mg/dL] 105.0 (57.0–226.0) 122.5 (69.0–231.0) 118.0 (57.0–226.0) > 0.05
HDL-cholesterol [mg/dL] 50.5 (29.0–80.0) 46.0 (28.0–66.0) 51.0 (36.0–72.0) > 0.05
Triglycerides [mg/dL] 88.5 (35.0–321.0) 130.5 (48.0–279.0)b 80.0 (41.0–364.0) 0.01
HOMA-IR 1.6 (0.5–6.1) 2.7 (1.4–6.2)c, d 1.7 (0.5–4.3) 0.002
AUCG [mg/dL/min] 3165.0 (2171.2–5572.5) 4612.5 (3585.0–6780.0)a 3172.5 (2141.2–4998.7) < 0.001
AUCI [µ/mL/min] 1074.3 (591.0–4015.1) 1558.8 (760.8–3522.0)b 973.1 (495.7–4688.2) 0.01
Matsuda ISI 6.8 (2.0–12.3) 3.5 (1.5–8.0)e 7.1 (1.7–17.9) < 0.001
FGF 21 [pg/mL] 143.3 ± 93.8 221.9 ± 171.7f 121.2 ± 119.8 0.01
Data are expressed as mean ± SD or median (min–max) according to distribution of the data. ap < 0.001, Group 2 vs. Group 1 and 3; bp < 0.05, group 2 vs. Group 
3;c p = 0.01, Group 2 vs. Group 3; d p = 0.003 Group 2 vs. Group 1; e p = 0.001 Group 2 vs. Group 1 and 3; f p = 0.02, Group 2 vs. Group 3. BMI — body mass index; 
WHR — waist-hip ratio; BP — blood pressure; FBG — fasting blood glucose; AUCG — area under curve glucose; AUCI — area under curve insulin; Matsuda ISI — 
Matsuda index of insulin sensitivity
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pendent variables revealed that BMI was the most 
predictive factor for plasma FGF 21levels (b = 0.41, 
r2 = 0.17, p < 0.001).
Discussion
FGF 21 has favourable effects on glucose and lipid 
metabolism by stimulating gluconeogenesis, fatty acid 
oxidation, and ketogenesis in the liver [15]. In a pro-
spective study from Chen et al. [9], increased FGF 21 
level has been proposed as an independent predictor 
for the development of T2DM. High FGF 21 concen-
trations have been previously shown in subjects with 
IGT compared to those with normal glucose tolerance 
[16]. As far as we know, in the previous literature there 
is no study investigating FGF 21 levels in FDR of pa-
tients with T2DM. In the present study, we found that 
prediabetic FDR of patients with T2DM had higher 
FGF 21 concentrations than normoglycaemic subjects. 
Our results indicate that circulating levels of FGF 21 
increase as glucose tolerance impairs because of insulin 
resistance in FDR of patients with T2DM. Therefore, 
FGF 21 may be involved in decreased insulin sensitiv-
ity in FDR of patients with T2DM. Normoglycaemic 
FDR of patients with T2DM also had higher levels of 
FGF 21 than normoglycaemic subjects without a his-
tory of T2DM in their FDR, but the difference was not 
statistically significant. This result suggests that insulin 
resistance may have more impact on the levels of FGF 21 
than genetic factors.
Alterations in some adipocytokines, such as 
adiponectin and visfatin, have been demonstrated in 
normoglycaemic FDR of patients with T2DM in previ-
ous studies [17, 18]. In our study, FGF 21 levels were 
not significantly increased in normoglycaemic FDR 
of patients with T2DM compared to normoglycaemic 
subjects without a history of T2DM in their FDR. The 
degree of obesity or variable insulin sensitivity in the 
subjects studied can be argued as the reasons of this 
discrepancy between previous studies and ours. 
Circulating FGF 21 levels have been shown to be as-
sociated with insulin resistance in previous reports [7–9, 
11, 19]. Consistently, in our study, plasma FGF 21 con-
centrations were observed to be positively correlated 
with HOMA-IR, AUCG, and AUCI and negatively with 
Matsuda ISI. Camporez et al. [20] suggested that FGF 
21 protects mice from lipid-induced liver and muscle 
insulin resistance as one of the possible pathogenetic 
mechanisms. Furthermore, recently, treatment with 
FGF 21 has been suggested as a novel therapy for the 
treatment of insulin resistance and T2DM [21]. 
Some studies have revealed positive associations 
between FGF 21 concentrations and BMI and adipos-
ity [7, 22, 23]. In our study, we showed that there was 
a significant association between FGF 21 levels and BMI. 
Moreover, in the regression analysis, BMI was found 
to be the most important factor affecting the levels of 
FGF 21. Our result emphasises the importance of obe-
sity for the alterations in FGF 21 levels. Regarding this 
association between FGF 21 and obesity, some authors 
suggested that there may be a FGF 21 resistance in obese 
subjects [24]. Therefore, future treatment modalities 
that can overcome this resistance may be an important 
step in the management of obesity. 
In our study, FGF 21 level was found to be signifi-
cantly higher in subjects with MS than those without 
MS. In accordance with our result, some studies have 
shown increased levels of FGF 21 in MS [25, 26]. Moreo-
ver, Bobbert et al. [27] proposed that FGF 21 may be 
a predictive factor for the development of MS in healthy 
individuals. The regulating peroxisome proliferator-
activated receptor gamma (PPAR-gamma) activity of 
FGF 21 has been suggested as an underlying mechanism 
in this association between FGF 21 and MS [28]. 
Our study has some limitations. Because of the 
cross-sectional design of our study, a causal relation-
ship between FGF 21 and insulin resistance and the 
development of T2DM cannot be established. The other 
limitation of the study was the relatively small sample 
size. However, our findings are important since there 
is lack of information about FGF 21 levels in FDR of 
patients with T2DM in the current literature. 
Conclusions
We demonstrated that prediabetic FDR of patients with 
T2DM have increased circulating FGF 21 concentrations 
and that there is a significant association between FGF 
21 and obesity and insulin sensitivity. Future prospec-
tive studies are needed to clarify the importance of 
increased FGF 21 in the development of metabolic 
disorders in these individuals.
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